Biopharmaceutical CMO & CRO Market Updates

Global Biopharmaceutical CMO & CRO Market size was valued at USD 32.4 billion in 2023 and is poised to grow from USD 34.31 billion in 2024 to USD 54.28 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032). 

Because of the presence of a significant number of established as well as medium- to small-sized CMOs and CROs, the market is fragmented. Several market players are privately held or are part of the portfolios of private equity companies. CMOs are incorporating automation and cutting-edge technology into their factories to boost project productivity and product quality. This has fueled big molecule producers' interest in CMOs to address the increased demand for biologics. Charles River Laboratories International, Inc.; PRA Health Sciences; ICON plc. Pharmaceutical Product Development, LLC; LabCorp; and Parexel International Corporation are engaged in offering contract research services for large molecule production. Market players focus on various business strategies including mergers, acquisitions, product launches, etc. For instance, in December 2021, Discovery Life Sciences completed and announced the acquisition of In Vitro ADMET Laboratories (IVAL). With this move, the company aims to expand its skilled workforce allowing them to competently cater to the rising outsourcing of research activities. Cerba HealthCare made a public statement in December 2021 on its acquisition of the Viroclinics-DDL company. With this, it has joined the CRO industry, with a focus on precision medicine for auto-immune illnesses. Lonza issued a news statement in November 2021 announcing the acquisition of the Exosomics Service Unit. This will increase its future potential to generate and manufacture exosomes. 'Lonza Group (Switzerland) ', 'Thermo Fisher Scientific (United States) ', 'Catalent (United States) ', 'WuXi Biologics (China) ', 'Samsung Biologics (South Korea) ', 'IQVIA (United States) ', 'Syneos Health (United States) ', 'ICON Plc (Ireland) ', 'Medpace Holdings (United States) ', 'Charles River Laboratories (United States) ', 'PPD (United States) ', 'Labcorp Drug Development (United States) ', 'Parexel International (United States) ', 'PRA Health Sciences (United States) ', 'BioNTech SE (Germany) ', 'Moderna, Inc. (United States) ', 'Gilead Sciences (United States) ', 'Regeneron Pharmaceuticals (United States) ', 'Vertex Pharmaceuticals (United States) ', 'Amgen Inc. (United States) '

Integration of New Bioprocessing Technologies and Single-Use Systems

New Product Development to Positively Impact the Market

North America had the greatest revenue share in 2021, accounting for almost 35% of overall sales. This might be attributed to the fact that there are several local service providers in the region. CMOs are in charge of producing a sizable portion of the authorised goods marketed in the United States. The creation of a number of small and mid-sized biopharmaceutical businesses (SMEs) that lack the capabilities and funds to build well-equipped facilities is troublesome. As a result, CMOs and SMEs in the United States have become increasingly dependent on one another, resulting in the United States market becoming the most dominating internationally.